TELA TELA Bio, Inc.

Nasdaq telabio.com


$ 1.56 $ 0.03 (2 %)    

Friday, 17-Oct-2025 15:59:50 EDT
QQQ $ 604.92 $ 3.94 (0.66 %)
DIA $ 461.73 $ 2.22 (0.48 %)
SPY $ 665.28 $ 3.75 (0.57 %)
TLT $ 91.09 $ -0.14 (-0.15 %)
GLD $ 391.28 $ -7.46 (-1.88 %)
$ 1.53
$ 1.49
$ 1.37 x 4
$ 1.60 x 50
$ 1.48 - $ 1.56
$ 0.86 - $ 3.26
39,502
na
60.61M
$ 0.45
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-11-2025 06-30-2025 10-Q
2 05-08-2025 03-31-2025 10-Q
3 03-21-2025 12-31-2024 10-K
4 11-08-2024 09-30-2024 10-Q
5 08-13-2024 06-30-2024 10-Q
6 05-10-2024 03-31-2024 10-Q
7 03-22-2024 12-31-2023 10-K
8 11-13-2023 09-30-2023 10-Q
9 08-10-2023 06-30-2023 10-Q
10 05-11-2023 03-31-2023 10-Q
11 03-23-2023 12-31-2022 10-K
12 11-10-2022 09-30-2022 10-Q
13 08-11-2022 06-30-2022 10-Q
14 05-11-2022 03-31-2022 10-Q
15 03-23-2022 12-31-2021 10-K
16 11-12-2021 09-30-2021 10-Q
17 08-12-2021 06-30-2021 10-Q
18 05-14-2021 03-31-2021 10-Q
19 03-25-2021 12-31-2020 10-K
20 11-12-2020 09-30-2020 10-Q
21 08-13-2020 06-30-2020 10-Q
22 05-15-2020 03-31-2020 10-Q
23 03-30-2020 12-31-2019 10-K
24 12-18-2019 09-30-2019 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 tela-bio-affirms-fy2025-sales-guidance-of-85000m-88000m-vs-86060m-est

TELA Bio (NASDAQ:TELA) affirms FY2025 sales outlook from $85.000 million-$88.000 million to $85.000 million-$88.000 million vs ...

 tela-bio-q2-eps-022-misses-018-estimate-sales-20197m-miss-20680m-estimate

TELA Bio (NASDAQ:TELA) reported quarterly losses of $(0.22) per share which missed the analyst consensus estimate of $(0.18) by...

 tela-bio-affirms-fy2025-sales-guidance-of-8500m-8800m-vs-8554m-est

TELA Bio (NASDAQ:TELA) affirms FY2025 sales outlook from $85.00 million-$88.00 million to $85.00 million-$88.00 million vs $85....

 tela-bio-q1-eps-025-misses-023-estimate-sales-1852m-beat-1736m-estimate

TELA Bio (NASDAQ:TELA) reported quarterly losses of $(0.25) per share which missed the analyst consensus estimate of $(0.23) by...

 tela-bio-launches-larger-surgical-mesh-to-simplify-complex-reconstructive-procedures

TELA Bio, Inc. (NASDAQ:TELA), a commercial-stage medical technology company focused on advancing soft-tissue reconstruction sol...

 canaccord-genuity-maintains-buy-on-tela-bio-lowers-price-target-to-7

Canaccord Genuity analyst Caitlin Cronin maintains TELA Bio (NASDAQ:TELA) with a Buy and lowers the price target from $12 to...

 citizens-capital-markets-maintains-market-outperform-on-tela-bio-lowers-price-target-to-7

Citizens Capital Markets analyst David Turkaly maintains TELA Bio (NASDAQ:TELA) with a Market Outperform and lowers the pric...

 piper-sandler-downgrades-tela-bio-to-neutral-lowers-price-target-to-2

Piper Sandler analyst Matt O'Brien downgrades TELA Bio (NASDAQ:TELA) from Overweight to Neutral and lowers the price tar...

 tela-bio-q4-2024-gaap-eps-023-misses-022-estimate-sales-17649m-miss-23166m-estimate

TELA Bio (NASDAQ:TELA) reported quarterly losses of $(0.23) per share which missed the analyst consensus estimate of $(0.22) by...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION